L Brådvik1, C Mattisson, M Bogren, P Nettelbladt. 1. Department of Clinical Sciences, Division of Psychiatry, Lundby Study, Lund University Hospital, Lund, Sweden. louise@bradvik.se
Abstract
OBJECTIVE: The long-term suicide risk of depression was evaluated in a community sample by severity and gender. METHOD: The Lundby study is a prospective, longitudinal cohort study on a population consisting of 3563 subjects. In 1947-1997 medium or severe depression according to the Lundby diagnostic system were registered in 503 subjects. The same subjects were also diagnosed according to DSM-IV showing major depressive disorder (MDD) in 293 and depressive disorder not otherwise specified (DDNOS) in 131 subjects. RESULTS: The overall long-term suicide risk varied from 5.6% to 6.8%. The long-term suicide risk was 3.1% for medium and 11.4% for severe 'Lundby depression', 3.7% for medium and 13.8% for severe MDD + DDNOS, 3.1% for medium and 13.7% for severe MDD. Severity and male sex were risk factors for suicide. CONCLUSION: Males with a severe depression showed a high long-term risk for suicide, around 20%.
OBJECTIVE: The long-term suicide risk of depression was evaluated in a community sample by severity and gender. METHOD: The Lundby study is a prospective, longitudinal cohort study on a population consisting of 3563 subjects. In 1947-1997 medium or severe depression according to the Lundby diagnostic system were registered in 503 subjects. The same subjects were also diagnosed according to DSM-IV showing major depressive disorder (MDD) in 293 and depressive disorder not otherwise specified (DDNOS) in 131 subjects. RESULTS: The overall long-term suicide risk varied from 5.6% to 6.8%. The long-term suicide risk was 3.1% for medium and 11.4% for severe 'Lundby depression', 3.7% for medium and 13.8% for severe MDD + DDNOS, 3.1% for medium and 13.7% for severe MDD. Severity and male sex were risk factors for suicide. CONCLUSION: Males with a severe depression showed a high long-term risk for suicide, around 20%.
Authors: C Fabbri; K E Tansey; R H Perlis; J Hauser; N Henigsberg; W Maier; O Mors; A Placentino; M Rietschel; D Souery; G Breen; C Curtis; L Sang-Hyuk; S Newhouse; H Patel; M Guipponi; N Perroud; G Bondolfi; M O'Donovan; G Lewis; J M Biernacka; R M Weinshilboum; A Farmer; K J Aitchison; I Craig; P McGuffin; R Uher; C M Lewis Journal: Pharmacogenomics J Date: 2017-11-21 Impact factor: 3.550
Authors: Edward S Friedman; Lori L Davis; Sidney Zisook; Stephen R Wisniewski; Madhukar H Trivedi; Maurizio Fava; A John Rush Journal: Eur Neuropsychopharmacol Date: 2011-09-14 Impact factor: 4.600
Authors: Warren D Taylor; Brian Boyd; Douglas R McQuoid; Kamil Kudra; Ayman Saleh; James R MacFall Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2015-05-08 Impact factor: 5.067
Authors: Doreen M Olvet; Denis Peruzzo; Binod Thapa-Chhetry; M Elizabeth Sublette; Gregory M Sullivan; Maria A Oquendo; J John Mann; Ramin V Parsey Journal: J Psychiatr Res Date: 2014-01-16 Impact factor: 4.791
Authors: Natalie Sachs-Ericsson; Jennifer L Hames; Thomas E Joiner; Elizabeth Corsentino; Nicole C Rushing; Emily Palmer; Ian H Gotlib; Edward A Selby; Steven Zarit; David C Steffens Journal: Am J Geriatr Psychiatry Date: 2013-02-06 Impact factor: 4.105
Authors: R C Kessler; H M van Loo; K J Wardenaar; R M Bossarte; L A Brenner; D D Ebert; P de Jonge; A A Nierenberg; A J Rosellini; N A Sampson; R A Schoevers; M A Wilcox; A M Zaslavsky Journal: Epidemiol Psychiatr Sci Date: 2016-01-26 Impact factor: 6.892